Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986148 · 1 trial · 1 indication
AEs leading to discontinuation, Death and Frequency of laboratory test toxicity grade shifting from baseline
SAEs leading to discontinuation, Death and Frequency of laboratory test toxicity grade shifting from baseline
AE leading to discontinuation, Death and Frequency of laboratory test toxicity grade shifting from baseline
SAEs leading to discontinuation, Death and Frequency of laboratory test toxicity grade shifting from baseline
| Arm | Type | Description |
|---|---|---|
| BMS-986148 intravenous infusion | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986148 | DRUG | Specified dose on specified days |
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Must have histological confirmation of advanced and/or metastatic solid tumors which are expected to express mesothelin * Must have received and either pro...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
BMS-986148 is an investigational small molecule being developed for the treatment of advanced cancer. It is a mesothelin-targeting antibody-drug conjugate (ADC) studied in a Phase 1 clinical trial. The drug is not approved and remains in clinical development for oncology indications.
BMS-986148 targets mesothelin, a protein expressed on the surface of certain cancer cells. As an antibody-drug conjugate, it is designed to deliver a cytotoxic agent to mesothelin-expressing tumors. This mechanism was evaluated in a Phase 1 study for advanced cancer.
BMS-986148 is developed by Bristol-Myers Squibb Company, traded on the New York Stock Exchange under the ticker BMY. The company sponsored the Phase 1 clinical trial of this investigational oncology drug.
BMS-986148 is in Phase 1 clinical development. The drug is investigational and has not been approved by regulatory authorities. A Phase 1 study of the mesothelin-ADC has been completed, but the drug remains in early-stage clinical testing.
BMS-986148 was studied in a single Phase 1 clinical trial registered as NCT02884726, titled "Phase 1 Study of Mesothelin-ADC." The trial enrolled 8 participants with advanced cancer in Japan and has been completed. It was an uncontrolled, non-randomized study.
BMS-986148 is referred to as a mesothelin-ADC in its clinical trial title, indicating it is an antibody-drug conjugate targeting mesothelin. The drug is also known by this descriptive name, which appears in the study registration for NCT02884726.